Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cost of Revenue (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Cost of Revenue data on record, last reported at $37.0 million in Q4 2025.

  • For Q4 2025, Cost of Revenue changed 0.39% year-over-year to $37.0 million; the TTM value through Dec 2025 reached $151.8 million, up 0.58%, while the annual FY2025 figure was $151.8 million, 0.58% up from the prior year.
  • Cost of Revenue reached $37.0 million in Q4 2025 per MRVI's latest filing, up from $36.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $53.3 million in Q4 2022 and bottomed at $30.4 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $38.1 million, with a median of $37.5 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: skyrocketed 98.52% in 2021, then tumbled 34.07% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $40.6 million in 2021, then surged by 31.06% to $53.3 million in 2022, then tumbled by 34.07% to $35.1 million in 2023, then grew by 5.87% to $37.2 million in 2024, then dropped by 0.39% to $37.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $37.0 million in Q4 2025, $36.0 million in Q3 2025, and $39.6 million in Q2 2025.